BELKIN Laser rebrands as BELKIN Vision

Article

The glaucoma treatment company rebrands to align more closely with goals and direction of the company.

BELKIN Laser rebrands as BELKIN Vision

In a strategic move by the company to align their name with their future, BELKIN Laser will now be known as BELKIN Vision. The Israel-based medical device company will continue to supply fast, accessible glaucoma laser treatment as well as reinforcing their focus on additional ophthalmic challenges.

BELKIN Vision made a splash in the glaucoma treatment industry with their fast, no-contact laser. While other glaucoma treatments—such as daily drops or invasive lasers—pose issues of poor patient adherence and significant time requirements, the BELKIN Vision DSLT (Direct SLT) enhances intraocular fluid drainage in about a second via delivery of a single laser beam to the limbus.

"When we started the company in 2013, we always imagined that it would transport us to the stage we're at today. Now, on the cusp of commercialization, we anticipate a multitude of exciting future applications and wanted to ensure that our company name aligned with that vision. We're confident that BELKIN Vision perfectly reflects our future plans and will capture the hearts and minds of our future customers," said Daria Lemann Blumenthal, CEO of BELKIN Vision.

For more information, visit BELKIN Vision’s website.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.